Soaring Eagle Acquisition Corp. focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was formerly known as Spinning Eagle Acquisition Corp and changed its name to Soaring Eagle Acquisition Corp. in February 2021. The company was founded in 2020 and is based in New York, New York.
IPO Year:
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
3 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)
3 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)
4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)
4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)
4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)
4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)
4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)
4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)
4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)
4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)
EFFECT - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)
424B3 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)
8-K - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)
EFFECT - Soaring Eagle Acquisition Corp. (0001830214) (Filer)
424B3 - Soaring Eagle Acquisition Corp. (0001830214) (Filer)
CERT - Soaring Eagle Acquisition Corp. (0001830214) (Filer)
8-A12B - Soaring Eagle Acquisition Corp. (0001830214) (Filer)
25 - Soaring Eagle Acquisition Corp. (0001830214) (Filer)
S-1/A - Soaring Eagle Acquisition Corp. (0001830214) (Filer)
POS AM - Soaring Eagle Acquisition Corp. (0001830214) (Filer)
Fastest customizable press release news feed in the world
Soaring Eagle Shareholder Approval Obtained, Closing Scheduled for September 16, 2021 Ginkgo Set to Begin Trading under NYSE: DNA on September 17, 2021 $1.633 billion in proceeds from the business combination represents the largest-ever biotechnology go-public transaction. Investors were led by Baillie Gifford, Putnam Investments, and funds and accounts managed by Counterpoint Global (Morgan Stanley Investment Management). Additional investors included ARK Investment Management LLC, ArrowMark Partners, Bain Capital Public Equity, Cascade Investment, Casdin Capital, Franklin Advisers, T. Rowe Price, and Viking Global Investors. Business combination with Ginkgo approved by Soaring Eagl
BOSTON and ADDIS ABABA, Ethiopia, Sept. 14, 2021 /PRNewswire/ -- The Africa Centres for Disease Control and Prevention (Africa CDC), a specialized technical institution of the African Union, and Ginkgo Bioworks, which is building the leading horizontal platform for cell programming, today announced a partnership to bolster the laboratory network capacity for African Union Member States. The partnership is aimed at supporting the continent's public health institutions with appropriate tools, training, and data infrastructure to leverage critical genomic sequencing technologies that will be implemented through Africa CDC Institute for Pathogen Genomics (IPG) and Ginkgo Bioworks. Gin
BOSTON, Sept. 10, 2021 /PRNewswire/ -- Ginkgo Bioworks ("Ginkgo"), which is building the leading horizontal platform for cell programming, today announced its readiness to continue scaling support for COVID testing in congregate settings in response to new emergency standards and recommendations issued by the Biden-Harris Administration. Ginkgo, which recently announced a business combination with Soaring Eagle Acquisition Corp. (NASDAQ:SRNG), serves customers across industries seeking to develop new and better products using biology. Last year, Ginkgo launched Concentric by Ginkgo, its public health and biosecurity initiative, to provide a response to the COVID-19 pandemic. Since then, Conc
LEXINGTON, Mass. and BOSTON, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ:AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections today announced the launch of SaponiQx, a subsidiary of Agenus, dedicated to driving innovation in novel adjuvant discovery and vaccine design, and its partnership with Ginkgo Bioworks, Inc. ("Ginkgo"), the leading horizontal platform for cell programming. Ginkgo, which recently announced a business combination with Soaring Eagle Acquisition Corp. (NASDAQ:SRNG), is enabling customers across industries to improve products and
BOSTON, Sept. 9, 2021 /PRNewswire/ -- Ginkgo Bioworks ("Ginkgo"), which is building the leading horizontal platform for cell programming, today announced the launch of Ayana Bio to enable a healthier future by harnessing bioactive compounds for use as complementary medicine to support human health and wellness. Ginkgo, which recently announced a business combination with Soaring Eagle Acquisition Corp. (NASDAQ:SRNG), has successfully launched several new companies across a variety of end-markets, bringing together funding from strategic and financial investors. The Ferment Consortium, a company creation studio that works with Viking Global Investors and Cascade Investment, both of whom are p
BOSTON, Sept. 9, 2021 /PRNewswire/ -- Ginkgo Bioworks ("Ginkgo"), which is building the leading horizontal platform for cell programming, today announced the launch of Verb Biotics ("Verb"), a probiotics innovation company that will identify and design new strains of probiotic bacteria with advanced properties for human nutrition, health, and wellness. Ginkgo, which recently announced a business combination with Soaring Eagle Acquisition Corp. (NASDAQ:SRNG), has successfully launched several new companies across a variety of end-markets, bringing together funding from strategic and financial investors. The Ferment Consortium, a company creation studio that works with Viking Global Investors
Extraordinary General Meeting to Be Held on September 14, 2021; Closing of Business Combination Expected to Occur on September 16, 2021 Shares of the Combined Company Expected to Begin Trading on NYSE under the ticker "DNA" on September 17, 2021 Soaring Eagle Acquisition Corp. (the "Company" or "Soaring Eagle") (NASDAQ:SRNGU, SRNG, SRNGW))) announced today that it had achieved a quorum for the extraordinary general meeting of the Company's shareholders to be held on September 14, 2021 (the "Special Meeting") in connection with its business combination (the "Business Combination") with Ginkgo Bioworks, Inc. ("Ginkgo") and that the shareholders who have submitted proxies to date on the
BOSTON, Sept. 7, 2021 /PRNewswire/ -- Tantu, a company engineering living biotherapeutic products to treat gastrointestinal diseases, and Ginkgo Bioworks ("Ginkgo"), which is building the leading horizontal platform for cell programming, today announced a partnership to accelerate the research and development of Tantu's therapeutic genes. Ginkgo, which recently announced a business combination with Soaring Eagle Acquisition Corp. (NASDAQ:SRNG), serves customers across industries seeking to develop new and better products using biology. Tantu is working to create an orally adm
BOSTON, Sept. 3, 2021 /PRNewswire/ -- Ginkgo Bioworks Inc. ("Ginkgo"), which is building the leading horizontal platform for cell programming and recently announced a business combination with Soaring Eagle Acquisition Corp. (NASDAQ:SRNG), today announced that management is scheduled to participate in the following upcoming conferences: Morgan Stanley Healthcare Conference on Thursday September 9, 2021, at 8:45 a.m. Eastern Time. Wells Fargo Healthcare Conference on Friday, September 10, 2021, at 2:00 p.m. Eastern Time. Bernstein ESG Conference on Wednesday, September 15, 2021
BERKELEY, Calif. and BOSTON, Sept. 2, 2021 /PRNewswire/ -- Cambium Biomaterials ("Cambium"), the company creating high-performance biomaterials, today announced a partnership with Ginkgo Bioworks, Inc. ("Ginkgo"), which is building the leading horizontal platform for cell programming. Ginkgo, which recently announced a business combination with Soaring Eagle Acquisition Corp. (NASDAQ:SRNG), serves customers across industries seeking to develop new and better products using biology. The partnership will leverage Ginkgo's Codebase and high-throughput facility to accelerate Cambium's discovery, development, manufacturing and commercialization of biomaterials that deliver superior performance an
Live finance-specific insights
BOSTON, Aug. 9, 2021 /PRNewswire/ -- Ginkgo Bioworks, Inc. ("Ginkgo"), which recently announced a business combination with Soaring Eagle Acquisition Corp. (NASDAQ:SRNG), announced that it will host a presentation reviewing results for the first six months of 2021 after the market closes on Wednesday, August 18, 2021, beginning at 4:30 p.m. ET. The presentation will include an overview of first half performance, recent updates, and a discussion on Ginkgo's business model and outlook. The presentation details and registration link will be available on Ginkgo's investor relation
This live feed shows all institutional transactions in real time.
SC 13D/A - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)
SC 13G - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)
SC 13G - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)
SC 13G - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)
SC 13D - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)
SC 13D - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)
SC 13D - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)
SC 13G - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)
SC 13G - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)
SC 13G - Soaring Eagle Acquisition Corp. (0001830214) (Subject)